Daiken Biomedical（7780）株式概要大建バイオメディカル株式会社は、健康食品の研究開発を行っている。 詳細7780 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性5/6配当金1/6報酬当社が推定した公正価値より35%で取引されている 過去1年間で収益は39%増加しました リスク分析高いレベルの非現金収入 4.16%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない 過去1年間で株主の希薄化は大幅に進んだ すべてのリスクチェックを見る7780 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,122 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA487,122 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$16.80382.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue NT$2.0bEarnings NT$337.2mAdvancedSet Fair ValueView all narrativesDaiken Biomedical Co., Ltd. 競合他社Grape King BioSymbol: TWSE:1707Market cap: NT$13.2bTCISymbol: TPEX:8436Market cap: NT$13.7bChlitina HoldingSymbol: TWSE:4137Market cap: NT$7.8bDr. Wu SkincareSymbol: TPEX:6523Market cap: NT$4.1b価格と性能株価の高値、安値、推移の概要Daiken Biomedical過去の株価現在の株価NT$16.8052週高値NT$35.5052週安値NT$16.00ベータ01ヶ月の変化-6.15%3ヶ月変化-6.67%1年変化-50.30%3年間の変化n/a5年間の変化n/aIPOからの変化-5.62%最新ニュースUpcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).最新情報をもっと見るRecent updatesUpcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Reported Earnings • Mar 11Full year 2025 earnings released: EPS: NT$0.51 (vs NT$0.24 in FY 2024)Full year 2025 results: EPS: NT$0.51 (up from NT$0.24 in FY 2024). Revenue: NT$1.90b (up 39% from FY 2024). Net income: NT$337.9m (up 217% from FY 2024). Profit margin: 18% (up from 7.8% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Personal Products industry in Asia.お知らせ • Mar 10Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026, at 09:00 Taipei Standard Time. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city TaiwanValuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.40, the stock trades at a trailing P/E ratio of 61.5x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 20% over the past year.Buy Or Sell Opportunity • Jan 27Now 24% undervaluedOver the last 90 days, the stock has risen 56% to NT$26.05. The fair value is estimated to be NT$34.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has declined by 20%.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$26.05, the stock trades at a trailing P/E ratio of 78.6x. Average forward P/E is 22x in the Personal Products industry in Taiwan. Total returns to shareholders of 51% over the past year.New Risk • Jan 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 112% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 152% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Upcoming Dividend • Nov 17Upcoming dividend of NT$1.70 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 30 December 2025. Payout ratio is a comfortable 75% and the cash payout ratio is 83%. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (5.6%).Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$1.06 (vs NT$0.80 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.06 (up from NT$0.80 in 3Q 2024). Revenue: NT$449.3m (up 53% from 3Q 2024). Net income: NT$69.4m (up 45% from 3Q 2024). Profit margin: 16% (in line with 3Q 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Personal Products industry in Asia.Buy Or Sell Opportunity • Oct 03Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to NT$188. The fair value is estimated to be NT$239, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last year. Earnings per share has declined by 9.8%.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to NT$219, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.お知らせ • Aug 21Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering.Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,615,000 Price\Range: TWD 158 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,512,000 Price(minimum): TWD 147.66Upcoming Dividend • Aug 18Upcoming dividend of NT$2.45 per shareEligible shareholders must have bought the stock before 25 August 2025. Payment date: 15 September 2025. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.6%).Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$0.65 (vs NT$1.05 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.65. Revenue: NT$454.9m (up 61% from 2Q 2024). Net income: NT$38.8m (up 13% from 2Q 2024). Profit margin: 8.5% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 39%After last week's 39% share price gain to NT$319, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.Upcoming Dividend • Jul 15Upcoming dividend of NT$2.19 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 15 August 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.7%).New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$221, the stock trades at a trailing P/E ratio of 54.7x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.Upcoming Dividend • Jun 10Upcoming dividend of NT$3.32 per shareEligible shareholders must have bought the stock before 17 June 2025. Payment date: 04 July 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (5.2%).Reported Earnings • Apr 25Full year 2024 earnings released: EPS: NT$2.43 (vs NT$10.32 in FY 2023)Full year 2024 results: EPS: NT$2.43 (down from NT$10.32 in FY 2023). Revenue: NT$1.36b (up 14% from FY 2023). Net income: NT$106.6m (down 34% from FY 2023). Profit margin: 7.8% (down from 14% in FY 2023). The decrease in margin was driven by higher expenses.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).お知らせ • Mar 08Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city Taiwan株主還元7780TW Personal ProductsTW 市場7D1.2%2.3%4.0%1Y-50.3%-25.5%84.6%株主還元を見る業界別リターン: 7780過去 1 年間で-25.5 % の収益を上げたTW Personal Products業界を下回りました。リターン対市場: 7780は、過去 1 年間で84.6 % のリターンを上げたTW市場を下回りました。価格変動Is 7780's price volatile compared to industry and market?7780 volatility7780 Average Weekly Movement2.9%Personal Products Industry Average Movement4.3%Market Average Movement6.5%10% most volatile stocks in TW Market12.1%10% least volatile stocks in TW Market2.7%安定した株価: 7780 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 7780の 週次ボラティリティ は、過去 1 年間で8%から3%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2018n/aTung-Ching Lincertifications.nutrasource.ca/certified-products/brand?id=DABI大研生物医学股份有限公司は健康食品の研究開発に従事している。本社は台湾の台北市。大研生物医学股份有限公司はサンフン・インフォ株式会社の子会社である。もっと見るDaiken Biomedical Co., Ltd. 基礎のまとめDaiken Biomedical の収益と売上を時価総額と比較するとどうか。7780 基礎統計学時価総額NT$13.61b収益（TTM）NT$337.22m売上高(TTM)NT$2.02b40.4xPER（株価収益率6.7xP/Sレシオ7780 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7780 損益計算書（TTM）収益NT$2.02b売上原価NT$762.71m売上総利益NT$1.26bその他の費用NT$924.23m収益NT$337.22m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.42グロス・マージン62.32%純利益率16.66%有利子負債／自己資本比率1.8%7780 の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.2%現在の配当利回り128%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/12 21:24終値2026/08/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Daiken Biomedical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Upcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).
New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.
Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.
New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Upcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).
New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.
Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.
New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Reported Earnings • Mar 11Full year 2025 earnings released: EPS: NT$0.51 (vs NT$0.24 in FY 2024)Full year 2025 results: EPS: NT$0.51 (up from NT$0.24 in FY 2024). Revenue: NT$1.90b (up 39% from FY 2024). Net income: NT$337.9m (up 217% from FY 2024). Profit margin: 18% (up from 7.8% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Personal Products industry in Asia.
お知らせ • Mar 10Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026, at 09:00 Taipei Standard Time. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city Taiwan
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.40, the stock trades at a trailing P/E ratio of 61.5x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 20% over the past year.
Buy Or Sell Opportunity • Jan 27Now 24% undervaluedOver the last 90 days, the stock has risen 56% to NT$26.05. The fair value is estimated to be NT$34.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has declined by 20%.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$26.05, the stock trades at a trailing P/E ratio of 78.6x. Average forward P/E is 22x in the Personal Products industry in Taiwan. Total returns to shareholders of 51% over the past year.
New Risk • Jan 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 112% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 152% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Upcoming Dividend • Nov 17Upcoming dividend of NT$1.70 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 30 December 2025. Payout ratio is a comfortable 75% and the cash payout ratio is 83%. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (5.6%).
Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$1.06 (vs NT$0.80 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.06 (up from NT$0.80 in 3Q 2024). Revenue: NT$449.3m (up 53% from 3Q 2024). Net income: NT$69.4m (up 45% from 3Q 2024). Profit margin: 16% (in line with 3Q 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Personal Products industry in Asia.
Buy Or Sell Opportunity • Oct 03Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to NT$188. The fair value is estimated to be NT$239, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last year. Earnings per share has declined by 9.8%.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to NT$219, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.
お知らせ • Aug 21Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering.Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,615,000 Price\Range: TWD 158 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,512,000 Price(minimum): TWD 147.66
Upcoming Dividend • Aug 18Upcoming dividend of NT$2.45 per shareEligible shareholders must have bought the stock before 25 August 2025. Payment date: 15 September 2025. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.6%).
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$0.65 (vs NT$1.05 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.65. Revenue: NT$454.9m (up 61% from 2Q 2024). Net income: NT$38.8m (up 13% from 2Q 2024). Profit margin: 8.5% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 39%After last week's 39% share price gain to NT$319, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.
Upcoming Dividend • Jul 15Upcoming dividend of NT$2.19 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 15 August 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.7%).
New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$221, the stock trades at a trailing P/E ratio of 54.7x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.
Upcoming Dividend • Jun 10Upcoming dividend of NT$3.32 per shareEligible shareholders must have bought the stock before 17 June 2025. Payment date: 04 July 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (5.2%).
Reported Earnings • Apr 25Full year 2024 earnings released: EPS: NT$2.43 (vs NT$10.32 in FY 2023)Full year 2024 results: EPS: NT$2.43 (down from NT$10.32 in FY 2023). Revenue: NT$1.36b (up 14% from FY 2023). Net income: NT$106.6m (down 34% from FY 2023). Profit margin: 7.8% (down from 14% in FY 2023). The decrease in margin was driven by higher expenses.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
お知らせ • Mar 08Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city Taiwan
